The Relationship of Overweight and Obesity to High Mortality Rates from Liver Cirrhosis in Mexico

Nahum Méndez-Sánchez; Claudia P Sánchez-Castillo; Antonio R Villa; Herlinda Madrigal; Beatriz Merino; Elsy García; Patricia López; Edgar Pichardo-Ontiveros; Misael Uribe

2004, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2004; 3 (2)

The Relationship of Overweight and Obesity to High Mortality Rates from Liver Cirrhosis in Mexico

Méndez-Sánchez N, Sánchez-Castillo CP, Villa AR, Madrigal H, Merino B, García E, López P, Pichardo-Ontiveros E, Uribe M

Texto completo

Cómo citar este artículo

Idioma: Ingles.
Referencias bibliográficas: 27
Paginas: 66-71
Archivo PDF: 163.59 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

Secretaría de Salud. Mortalidad 1999, México, DF: SSA, 1999.
Méndez-Sánchez N, Aguilar-Ramírez JR, Aguirre J, Bosques-Padilla F Contreras AM, Dehesa M, et al. Etiología de la Cirrosis en México. Rev Gastroenterol Méx 2002;
Kodali VP, Gordon SC, Silverman AL, McCray DG. Cryptogenic liver disease in the United States: further evidence for non-A, non-B, non-C hepatitis. Am J Gastroenterol 1994; 89: 1836-1839.
Saunders JB, Walters JR, Davies AP, Paton A. A twenty year prospective study of cirrhosis. Br Med J 1981; 282: 263-266.
Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
Bonkovsky H, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht R, Banner B. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-429.
Weltman M, Farrell G, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-133.
Sanchez-Castillo CP, Velazquez-Monroy O, Berber A, Lara-Esqueda A, Tapia-Conyer R, James WP; Encuesta Nacional de Salud (ENSA) 2000 Working Group. Anthropometric cutoff points for predicting chronic diseases in the Mexican National Health Survey 2000. Obes Res 2003; 11: 442-51.
Méndez-Sánchez N, Uribe M. OBESIDAD. Epidemiología, Fisiopatología y Manifestaciones Clínicas. El Manual Moderno, México 2002.
Ludwig J, Viggiano T, McGill D, Ott B. Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
Byron D, Minuk G. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 1996; 24: 813-815.
Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 1992; 27: 521-528.
Daniel S, Ben-Menachem T, Vasudevan G, Ma C, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-3014.
Wanless I, Lentz J. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research. Principles and Quantitative Methods. Lifetime Learning Publications. New York, 1982. pp 78-81.
Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied Regression Analysis and Other Multivariable Methods. 3rd ed. Duxbury Press. New York, 1998. pp 39-60.
Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999; 282: 1519-1522.
Obesity: preventing and managing the global epidemic. Report of the WHO Consultation on Obesity. Geneva, Switzerland: WHO, 1997.
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
Angulo P. Treatment of nonalcoholic fatty liver disease. Ann Hepatol 2001; 1: 12-19.
Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-11.
Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 663-78.
Teish A, Mae Diehl A. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 679-90.
Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 2557-2562.
Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoeck JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, Diehl AM. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-5700.
Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.